Kenvue Inc. (NYSE:KVUE) Shares Bought by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado raised its position in Kenvue Inc. (NYSE:KVUE) by 8.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 262,892 shares of the company’s stock after acquiring an additional 19,591 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Kenvue were worth $4,779,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in KVUE. Vanguard Group Inc. lifted its stake in shares of Kenvue by 12.0% in the first quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock valued at $3,579,294,000 after purchasing an additional 17,908,497 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Kenvue by 23.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock valued at $2,887,773,000 after purchasing an additional 25,238,112 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of Kenvue by 9.6% in the second quarter. Massachusetts Financial Services Co. MA now owns 79,863,967 shares of the company’s stock valued at $1,451,927,000 after purchasing an additional 7,023,047 shares during the period. Wellington Management Group LLP lifted its stake in shares of Kenvue by 6.7% in the fourth quarter. Wellington Management Group LLP now owns 76,501,956 shares of the company’s stock valued at $1,647,087,000 after purchasing an additional 4,815,126 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of Kenvue by 11.1% in the first quarter. JPMorgan Chase & Co. now owns 68,319,998 shares of the company’s stock valued at $1,466,147,000 after purchasing an additional 6,825,611 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE stock opened at $23.02 on Monday. The company has a market capitalization of $44.08 billion, a P/E ratio of 29.51, a PEG ratio of 2.92 and a beta of 1.40. The company has a 50-day simple moving average of $20.92 and a 200 day simple moving average of $19.96. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $23.55. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The company had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same period in the prior year, the company earned $0.32 EPS. Kenvue’s revenue was down .3% on a year-over-year basis. Sell-side analysts predict that Kenvue Inc. will post 1.08 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.56%. This is an increase from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Wednesday, August 14th. Kenvue’s dividend payout ratio is presently 105.13%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several recent research reports. Royal Bank of Canada restated an “outperform” rating and set a $24.00 target price on shares of Kenvue in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. UBS Group boosted their target price on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. lifted their price target on shares of Kenvue from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, Citigroup lowered their target price on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $21.44.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.